NASDAQ:MRSN Mersana Therapeutics - MRSN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.13 -0.06 (-1.43%) (As of 03/24/2023 08:51 PM ET) Add Compare Share Share Today's Range$3.92▼$4.1650-Day Range$4.13▼$7.0252-Week Range$2.68▼$8.34Volume2.54 million shsAverage Volume1.30 million shsMarket Capitalization$446.16 millionP/E RatioN/ADividend YieldN/APrice Target$14.71 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Mersana Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside256.3% Upside$14.71 Price TargetShort InterestBearish6.46% of Shares Sold ShortDividend StrengthN/ASustainability-0.69Upright™ Environmental ScoreNews Sentiment0.63Based on 3 Articles This WeekInsider TradingSelling Shares$164,847 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.97) to ($1.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.14 out of 5 starsMedical Sector468th out of 995 stocksPharmaceutical Preparations Industry217th out of 482 stocks 3.5 Analyst's Opinion Consensus RatingMersana Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.71, Mersana Therapeutics has a forecasted upside of 256.3% from its current price of $4.13.Amount of Analyst CoverageMersana Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.46% of the outstanding shares of Mersana Therapeutics have been sold short.Short Interest Ratio / Days to CoverMersana Therapeutics has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Mersana Therapeutics has recently increased by 20.14%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMersana Therapeutics does not currently pay a dividend.Dividend GrowthMersana Therapeutics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMersana Therapeutics has received a 58.72% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Mersana Therapeutics is -0.69. Previous Next 2.0 News and Social Media Coverage News SentimentMersana Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Mersana Therapeutics this week, compared to 2 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mersana Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $164,847.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Mersana Therapeutics is held by insiders.Percentage Held by Institutions92.40% of the stock of Mersana Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mersana Therapeutics are expected to grow in the coming year, from ($1.97) to ($1.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mersana Therapeutics is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mersana Therapeutics is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMersana Therapeutics has a P/B Ratio of 4.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Mersana Therapeutics (NASDAQ:MRSN) StockMersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.Read More Receive MRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MRSN Stock News HeadlinesMarch 23, 2023 | americanbankingnews.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Given Average Rating of "Buy" by BrokeragesMarch 20, 2023 | americanbankingnews.comMersana Therapeutics (NASDAQ:MRSN) Stock Rating Upgraded by JPMorgan Chase & Co.March 27, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...March 16, 2023 | msn.comJP Morgan Upgrades Mersana Therapeutics (MRSN)March 16, 2023 | msn.comMersana upgraded at JPMorgan ahead of ovarian cancer readout for lead assetMarch 16, 2023 | bizjournals.comThe Petri Dish: Patient death halts cancer drug trial; Biogen Alzheimer's drug gets boostMarch 14, 2023 | finanznachrichten.deMersana Therapeutics, Inc.: Mersana Therapeutics Provides Statement About SVBMarch 13, 2023 | markets.businessinsider.comMersana Announces FDA Clinical Hold For Phase 1 Trial Of XMT-2056March 27, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...March 13, 2023 | reuters.comU.S. FDA places Mersana's cancer drug trial on hold following deathMarch 13, 2023 | marketwatch.comMersana Therapeutics Study on FDA Hold After Patient Death >MRSNMarch 13, 2023 | finance.yahoo.comMersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical TrialMarch 13, 2023 | finance.yahoo.comUPDATE 1-U.S. FDA places Mersana's cancer drug trial on hold following deathMarch 10, 2023 | finance.yahoo.comMersana Therapeutics Provides Statement About SVBMarch 3, 2023 | finance.yahoo.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2022 Earnings Call TranscriptMarch 1, 2023 | seekingalpha.comMersana Therapeutics Q4 2022 Earnings PreviewMarch 1, 2023 | finance.yahoo.comQ4 2022 Mersana Therapeutics Inc Earnings CallMarch 1, 2023 | finance.yahoo.comMersana Therapeutics Full Year 2022 Earnings: US$2.18 loss per share (vs US$2.41 loss in FY 2021)February 28, 2023 | msn.comMersana Therapeutics GAAP EPS of -$0.44 beats by $0.05, revenue of $14.69M beats by $1.02MFebruary 28, 2023 | finance.yahoo.comMersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial ResultsFebruary 21, 2023 | finance.yahoo.comMersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023February 16, 2023 | nasdaq.comAvoro Capital Advisors Now Owns 7.60% of Mersana Therapeutics (MRSN)February 1, 2023 | finance.yahoo.comMersana Therapeutics Initiates Expansion Portion of UPGRADE-A Combination Clinical Trial in Platinum-Sensitive Ovarian CancerJanuary 25, 2023 | finanznachrichten.deMersana Therapeutics, Inc.: Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing TumorsJanuary 25, 2023 | finance.yahoo.comMersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing TumorsJanuary 16, 2023 | finance.yahoo.comZai Lab Limited Unsponsored ADR (ZLAB) Soars 17.6%: Is Further Upside Left in the Stock?January 6, 2023 | finance.yahoo.comMersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected MilestonesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MRSN Company Calendar Last Earnings2/28/2023Today3/26/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRSN CUSIPN/A CIK1442836 Webwww.mersana.com Phone(617) 498-0020FaxN/AEmployees169Year FoundedN/APrice Target and Rating Average Stock Price Forecast$14.71 High Stock Price Forecast$20.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+256.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-204,210,000.00 Net Margins-768.26% Pretax Margin-768.26% Return on Equity-178.80% Return on Assets-70.43% Debt Debt-to-Equity Ratio0.27 Current Ratio3.49 Quick Ratio3.49 Sales & Book Value Annual Sales$26.58 million Price / Sales16.79 Cash FlowN/A Price / Cash FlowN/A Book Value$0.92 per share Price / Book4.49Miscellaneous Outstanding Shares108,030,000Free Float103,273,000Market Cap$446.16 million OptionableNot Optionable Beta1.82 Key ExecutivesAnna ProtopapasPresident, Chief Executive Officer & DirectorBrian DeSchuytnerChief Financial Officer & Senior Vice PresidentTimothy B. LowingerChief Science & Technology OfficerArvin YangChief Medical Officer & Senior Vice PresidentAlejandra Veronica CarvajalSecretary, Chief Legal Officer & Senior VPKey CompetitorsBicycle TherapeuticsNASDAQ:BCYCBiomea FusionNASDAQ:BMEACogent BiosciencesNASDAQ:COGTMacroGenicsNASDAQ:MGNXHarrow HealthNASDAQ:HROWView All CompetitorsInsiders & InstitutionsVoya Investment Management LLCBought 47,610 shares on 2/28/2023Ownership: 0.288%Macquarie Group Ltd.Sold 3,793 shares on 2/21/2023Ownership: 0.150%Point72 Middle East FZEBought 9,566 shares on 2/16/2023Ownership: 0.010%Public Employees Retirement System of OhioSold 4,125 shares on 2/15/2023Ownership: 0.018%Metropolitan Life Insurance Co NYBought 1,750 shares on 2/15/2023Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions MRSN Stock - Frequently Asked Questions Should I buy or sell Mersana Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MRSN shares. View MRSN analyst ratings or view top-rated stocks. What is Mersana Therapeutics' stock price forecast for 2023? 6 Wall Street analysts have issued twelve-month price targets for Mersana Therapeutics' shares. Their MRSN share price forecasts range from $10.00 to $20.00. On average, they predict the company's stock price to reach $14.71 in the next year. This suggests a possible upside of 256.3% from the stock's current price. View analysts price targets for MRSN or view top-rated stocks among Wall Street analysts. How have MRSN shares performed in 2023? Mersana Therapeutics' stock was trading at $5.86 at the start of the year. Since then, MRSN shares have decreased by 29.5% and is now trading at $4.13. View the best growth stocks for 2023 here. When is Mersana Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our MRSN earnings forecast. How were Mersana Therapeutics' earnings last quarter? Mersana Therapeutics, Inc. (NASDAQ:MRSN) announced its quarterly earnings data on Tuesday, February, 28th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.03. The business earned $14.69 million during the quarter, compared to the consensus estimate of $27.85 million. Mersana Therapeutics had a negative trailing twelve-month return on equity of 178.80% and a negative net margin of 768.26%. What ETFs hold Mersana Therapeutics' stock? ETFs with the largest weight of Mersana Therapeutics (NASDAQ:MRSN) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Future Gen 200 ETF (QQQS), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ) and ProShares Ultra Nasdaq Biotechnology (BIB). What is Anna Protopapas' approval rating as Mersana Therapeutics' CEO? 3 employees have rated Mersana Therapeutics Chief Executive Officer Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among the company's employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Mersana Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Ovid Therapeutics (OVID), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Marvell Technology (MRVL), Inovio Pharmaceuticals (INO), DocuSign (DOCU), Immunomedics (IMMU) and Marinus Pharmaceuticals (MRNS). When did Mersana Therapeutics IPO? (MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Mersana Therapeutics' stock symbol? Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN." Who are Mersana Therapeutics' major shareholders? Mersana Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (3.67%), Marshall Wace LLP (2.53%), Braidwell LP (1.87%), Morgan Stanley (1.76%), Geode Capital Management LLC (1.71%) and Silverarc Capital Management LLC (1.14%). Insiders that own company stock include Alejandra Carvajal, Andrew A F Hack, Anna Protopapas, Arvin Yang, Ashish Mandelia, Brian Deschuytner, Eva M Jack, Lawrence M Alleva, Lawrence M Alleva, Scott D Sandell, Timothy B Lowinger and Tushar Misra. View institutional ownership trends. How do I buy shares of Mersana Therapeutics? Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Mersana Therapeutics' stock price today? One share of MRSN stock can currently be purchased for approximately $4.13. How much money does Mersana Therapeutics make? Mersana Therapeutics (NASDAQ:MRSN) has a market capitalization of $446.16 million and generates $26.58 million in revenue each year. The company earns $-204,210,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis. How many employees does Mersana Therapeutics have? The company employs 169 workers across the globe. How can I contact Mersana Therapeutics? Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.mersana.com. The company can be reached via phone at (617) 498-0020 or via email at ir@mersana.com. This page (NASDAQ:MRSN) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.